Lefranc D, Vermersch P, Dallongeville J, Daems-Monpeurt C, Petit H, Delacourte A
INSERM U422, Faculté de Médecine, Lille, France.
Neurosci Lett. 1996 Jul 12;212(2):91-4. doi: 10.1016/0304-3940(96)12774-9.
Apolipoprotein E (Apo E), one of the major structural and functional apolipoproteins, has recently been implicated in the pathogenesis of Alzheimer's disease (AD). Several studies revealed that Apo E4 isoform is associated with the pathogenic process in AD. A significant reduction of cerebrospinal fluid (CSF) Apo E level in AD patients has been reported in two studies. To further investigate the physiopathological significance of such a variation of Apo E concentration in the CSF, we performed a quantification of Apo E by an enzyme linked immunosorbent assay (ELISA). There were no significant differences in CSF Apo E level between AD cases and control subjects or patients suffering from other neurological diseases. Gender, age and Apo E phenotype explained none of CSF Apo E concentration variability.
载脂蛋白E（Apo E）是主要的结构和功能载脂蛋白之一，最近被认为与阿尔茨海默病（AD）的发病机制有关。多项研究表明，Apo E4亚型与AD的致病过程相关。两项研究报告称，AD患者脑脊液（CSF）中Apo E水平显著降低。为了进一步研究CSF中Apo E浓度这种变化的生理病理学意义，我们采用酶联免疫吸附测定（ELISA）对Apo E进行了定量分析。AD病例与对照受试者或患有其他神经系统疾病的患者之间，CSF中Apo E水平没有显著差异。性别、年龄和Apo E表型均无法解释CSF中Apo E浓度的变异性。
